Rilutek (riluzole), the first drug approved for amyotrophic lateral sclerosis

Aventis is now marketing Rilutek (riluzole), the first drug approved for amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

ALS is a progressive, degenerative nerve disease...leading to muscle weakness, paralysis, and eventually death.

ALS is thought to be caused by excess glutamate, the primary excitatory neurotransmitter. Too much glutamate damages the nerves.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote